May 10th 2024
A greater shift from paper records and physical assets is achievable.
Verona Pharma Receives $650M Investment from Oaktree Capital Management and OMERS Life Sciences
May 9th 2024Strategic financing from Oaktree Capital Management and OMERS Life Sciences is expected to support the US launch of ensifentrine, Verona’s promising chronic obstructive pulmonary disease treatment.
Assessing LP-284 with RADR for NHL and Other Targeted Cancers
May 8th 2024In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, explains which specific endpoints they'll be looking at in the Phase I trial to assess LP-284's potential efficacy and how the insights gained will be fed back into RADR®
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
The Quest for Greater Channel Visibility in Pharma
May 7th 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, discusses how more granular insights into channel, tracing, and chargeback data can help drugmakers make smarter provider and payer contracting decisions.